Garijo starts as Sanofi CEO with window to ease reliance on Dupixent

Sanofi's New CEO Belén Garijo Tackles Post-Dupixent Strategy

Belén Garijo takes over as Sanofi CEO on April 29, facing the critical challenge of preparing the company for life after Dupixent's patent expiry, expected as early as 2031. Dupixent, an autoimmune blockbuster marketed with Regeneron, generated €15.7 billion ($18.4 billion) in sales in 2025, with a 31% increase in Q1. Garijo's strategy will involve leveraging a substantial M&A budget, potentially up to €25 billion for commercial assets, to acquire new growth drivers and diversify Sanofi's portfolio, following setbacks in the pipeline under the previous CEO, Paul Hudson. The company also has a patent defense strategy for Dupixent extending to 2045.

• Dupixent remains a significant growth driver for Sanofi, with 2025 sales reaching €15.7 billion ($18.4 billion) and a 31% jump in Q1. Despite its strong performance, the company is preparing for potential biosimilar competition as early as 2031. Sanofi has detailed a robust patent defense strategy, leveraging over 50 patents that extend to 2045, with Regeneron utilizing expertise from the Humira intellectual property team.
• Sanofi's CFO, François-Xavier Roger, confirmed the company's financial flexibility, indicating a capacity to spend up to €15 billion on deals while maintaining its credit rating. This ceiling could increase to €25 billion if Sanofi acquires a commercialized asset, suggesting the potential for its largest acquisition since 2004. This M&A firepower is crucial for Garijo to acquire new assets and reinvigorate the pipeline to reduce reliance on Dupixent.
• Belén Garijo's appointment as CEO on April 29 follows the departure of Paul Hudson amidst pipeline setbacks. Her primary mandate is to diversify Sanofi's portfolio and secure future growth beyond Dupixent's patent expiry. Her previous experience as CEO of Merck KGaA, where she emphasized diversification and a 'string of pearls' M&A approach, offers clues to her potential strategy, contrasting with Sanofi's recent focus on innovative medicines.

Identifying Unmet Needs in Autoimmune Conditions for Sanofi's Growth

Recent literature highlights significant unmet medical needs across multiple autoimmune conditions, with distinct patient populations requiring targeted therapeutic approaches. These gaps span from symptom management to novel therapeutic modalities, indicating substantial opportunities for pharmaceutical innovation.

• Fatigue management in systemic lupus erythematosus (SLE) represents a critical unmet need, with fatigue being the most prevalent symptom (84.9%) yet notably under-addressed in current treatment plans, alongside limited access to non-pharmacological therapies

• Rheumatoid arthritis treatment limitations persist with conventional therapies showing insufficient efficacy, severe side effects, higher dosing requirements, and frequent administration schedules, despite numerous investigations entering successful clinical trials with limited FDA approvals reaching market

• Disease flare management in SLE remains problematic, with only 7.9% of patients reporting no disease flares over five years, contrasting sharply with previous remission rate literature and highlighting the need for more effective disease-modifying approaches

• NAADP signaling pathway inhibitors represent an unexplored therapeutic target for autoimmune diseases, with no pharmacologic inhibitors currently available for clinical trials despite proposed therapeutic potential in T cell modulation

• Type 1 diabetes early intervention shows promise with teplizumab as the first therapy to delay disease onset by targeting autoimmunity in presymptomatic stage 2 patients, delaying progression by a median of 2 years when initiated before significant β-cell loss

• Enhanced patient-healthcare provider communication emerges as a critical need for optimizing autoimmune disease management, with 67.5% of SLE patients expressing treatment contentment while simultaneously indicating significant unmet needs

• Vulnerability during health crises became apparent during COVID-19, with autoimmune patients showing significantly increased mortality rates and healthcare spending, highlighting the need for pandemic-resilient care strategies

Garijo's Strategy: Targeting Novel Autoimmune Mechanisms for Pipeline Growth

Recent research has revealed multiple promising therapeutic targets for autoimmune diseases through advanced genomic and proteomic analyses. These discoveries span from novel protein targets identified through large-scale association studies to emerging cellular mechanisms and regulatory pathways that could transform autoimmune treatment approaches.

• Proteome-wide association studies identified 35 genetically regulated proteins associated with rheumatoid arthritis risk, including 10 potentially causal candidates and six novel proteins not previously implicated in genome-wide association studies: FCRL3, ICOSLG, MAPK3, WISP1, FAM213A, and IL1RN

• ICOSLG emerged as a particularly druggable target with AMG-557 demonstrating superior anti-inflammatory and anti-rheumatic activity, supported by identification of 160 drug-gene interactions for rheumatoid arthritis therapeutic development

• Myeloid cell subsets represent a new therapeutic frontier, with single-cell RNA sequencing analysis of 351,905 myeloid cells across 14 autoimmune diseases identifying 13 distinct cell subsets with unique immunological profiles and varying risk predispositions

• Dysregulated co-expression modules in monocyte function offer therapeutic repurposing opportunities, particularly a module linked to myeloid cell activation that is consistently upregulated across autoimmune disorders

• Interleukin-1 (IL-1) inhibitors have gained regulatory approval for treating recurrent/refractory pericarditis in inflammatory heart diseases, demonstrating the clinical viability of targeted anti-cytokine therapies over broad immunosuppressants

• Exosomal non-coding RNAs (microRNAs, long non-coding RNAs, and circular RNAs) have emerged as critical regulatory targets that modulate immune regulation, oxidative stress, autophagy, and cell cycle processes across multiple autoimmune conditions including SLE, RA, T1DM, IBD, and Sjögren's syndrome

Beyond Autoimmune: Expanding Dupixent's MoA to New Indications

Dupixent's mechanism of action—blocking IL-4 and IL-13 mediated pathways—is being explored across multiple non-autoimmune indications, leveraging its ability to target underlying type 2 inflammatory responses. These trials employ diverse intervention models ranging from adjunct therapy approaches to monotherapy regimens, with dosing strategies tailored to specific conditions.

Sanofi's M&A Play: Securing Growth Beyond a Blockbuster

Sanofi stands at a pivotal juncture, with its new CEO facing the formidable task of steering the company through the impending patent expiry of Dupixent, a drug that has become a cornerstone of its revenue. Dupixent, a blockbuster biologic targeting the IL-4Rα subunit, has revolutionized the treatment landscape for type 2 inflammatory conditions such as moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its long-term efficacy and favorable safety profile have cemented its position as a leading therapy, driving substantial sales growth and demonstrating high drug survival rates in real-world settings. However, with patent expiry looming as early as 2031, Sanofi faces a significant revenue gap. The company's strategy, spearheaded by a substantial M&A budget, signals an aggressive pursuit of new growth drivers to diversify its portfolio. This proactive approach is critical, not only to mitigate the impact of the patent cliff but also to maintain competitiveness in an increasingly crowded immunology market. The literature indicates a growing pipeline of biologics and small molecule targeted therapies for Dupixent's indications, some of which may offer comparable or even superior efficacy, posing a risk of market share erosion and pricing pressure. Sanofi's dual approach of patent defense extending to 2045, alongside strategic acquisitions, aims to maximize Dupilumab's lifecycle while building future franchises. The success of this strategy will hinge on identifying and integrating assets that can leverage Sanofi's established expertise and commercial infrastructure in allergic diseases. While Dupixent's real-world data consistently show reduced healthcare costs, the nuances of its safety profile, including reported conjunctivitis, underscore the importance of differentiated profiles for future acquisitions. This period will define Sanofi's trajectory in the post-Dupixent era, demanding astute strategic execution to secure sustainable growth.